Law360 (April 13, 2018, 11:17 PM EDT) -- The Federal Circuit on Friday upheld a patent covering Vanda Pharmaceuticals Inc.’s schizophrenia drug Fanapt, finding it met the U.S. Supreme Court’s Mayo standard by outlining a specific method of using natural phenomena for treatment.
A three-judge panel ruled 2-1 that U.S. Patent Number 8,586,610 covers the use of a patient’s genotype to tailor dosage, but it specifically tells doctors how to harness that relationship and use it in treatments rather than just describing the natural factors themselves.
The Mayo decision requires courts to look at...
Vanda Schizophrenia Drug Patentable, Fed. Circ. Says
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
